Florida health authorities confirmed the state's first 2026 fatality from Vibrio vulnificus involving a Palm Beach County resident, as summer heat drives a doubling of coastal bacterial infection cases.
International researchers led by QIMR Berghofer’s Simon Phipps discovered breastmilk protein osteopontin enhances infant immune cells via gut microbiome changes, suggesting formula improvements; study funded by Nestlé and published in Cell.
Starlet sea anemones use specialized mobile nematosomes and the cJun gene to selectively identify and destroy harmful bacteria while preserving beneficial microbes, challenging the belief that targeted immunity is exclusive to vertebrates' adaptive immune systems and pushing back its evolutionary timeline.
Researchers from Heinrich Heine University Düsseldorf and Kiel University discovered that the starlet sea anemone, Nematostella vectensis, uses specialized mobile cell structures called nematosomes to selectively identify and destroy harmful bacteria while preserving beneficial ones. This challenges the long-held assumption that targeted immune discrimination requires the complex adaptive immune system of vertebrates, pushing back the evolutionary timeline for such capabilities by hundreds of millions of years.
A global study led by the Murdoch Children’s Research Institute analyzed over 100,000 infection samples from children across 82 countries, revealing a significant increase in antibiotic resistance between 2004 and 2022. The research highlights the growing threat to children's health, particularly from bacteria like Acinetobacter baumannii and Klebsiella.
Anti-aging millionaire Bryan Johnson disclosed he has autoimmune gastritis (AIG), where his immune system attacks his stomach lining. He explained the condition, often undetected, can cause deficiencies and increase cancer risk. Johnson detailed his decade-long struggle with low ferritin levels, finally diagnosed through endoscopy and biopsies, and his experimental approach to treating AIG.
A comprehensive review of IVF add-ons found most lack reliable evidence of effectiveness, offering false hope and financial strain to patients. Only three showed weak evidence of possible benefit.
Poolbeg Pharma will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS), a dangerous side-effect of cancer immunotherapy. The drug could improve patient safety and save healthcare systems millions by allowing treatment outside specialist centers.
Five NHS patients in England with severe lupus are in remission after receiving CAR T-cell therapy, a groundbreaking treatment that genetically modifies immune cells to reset the immune system, offering hope for a potential cure.
An AI-designed universal vaccine targeting SARS, MERS, and COVID-19 showed modest immune effects in a small, first-in-human trial, offering potential for future pandemic prevention.
A new experimental drug in a UK clinical trial aims to remove the "invisibility cloak" that cancer cells use to hide from the immune system. In early trials with 83 late-stage cancer patients, some saw significant tumor shrinkage, suggesting a new direction for cancer immunotherapy.
Adults are consuming bovine colostrum, the first milk mammals produce, for purported health benefits like improved gut health and immunity. While early research shows promise, experts caution that more studies are needed and lifestyle changes should be prioritized.
Diagnosed HIV positive at 22 in 1986, the author, now 62, is one of the rare 'elite controllers' who remain undetectable without antiretroviral drugs. He shares his journey of survival, survivor's guilt, and his involvement in research aiming for an HIV cure.
CAR T cell therapy, initially for cancer, shows promise for autoimmune diseases like MS. While offering hope, it carries risks and uncertainties regarding efficacy and long-term side effects, with costs also being a significant challenge.
Research suggests routine vaccines may reduce dementia risk via 'trained immunity', enhancing innate immune responses to prevent neuro-inflammation.
A new UK and US-based cancer trial, named Mighty, is set to recruit up to 60 children and young people with difficult-to-treat solid tumours. The study will use CAR T-cell immunotherapy to train immune systems to fight rare and aggressive cancers, offering a "real sense of hope" for new treatments.
